The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.<\/p>\n
0757 GMT \u2013 The muted response to Innovent\u2019s cancer-drug deal with Takeda looks like a buying opportunity to Citi analysts. With an over US$1 billion upfront payment from Takeda, \u201cthe deal is the second-largest ranked by biobucks between pharma and biotech companies,\u201d Wangbin Zhou and others write. They attribute the subdued stock reaction to concerns about Takeda not being a leading oncology player and the high R&D costs of global clinical trials. But Citi reckons Takeda management has rich experience in immuno-oncology, and the codevelopment should help Innovent establish global clinical development and commercialization capability. That could pave the way for it to become a global force in biopharma. Citi keeps a buy call with a HK$110 target. Shares are last at HK$86.90. (fabiana.negrinochoa@wsj.com<\/a>)<\/p>\n Copyright \u00a92025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…\n","protected":false},"author":2,"featured_media":139573,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[41573,110,41570,13782,41565,7266,18,41571,3334,135,475,474,82485,82483,82484,19,41586,17,3544,82489,3865,82490,82488,1474,12490,82482,2900,9436,44285,7981,82487,172,82486,82491,827,26243,41580],"class_list":{"0":"post-139572","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ce-industry-news-filter","9":"tag-cancer","10":"tag-content-types","11":"tag-corporate","12":"tag-corporate-industrial-news","13":"tag-development","14":"tag-eire","15":"tag-factiva-filters","16":"tag-general-news","17":"tag-health","18":"tag-health-care","19":"tag-healthcare","20":"tag-healthcare-provision","21":"tag-healthcare-life-sciences","22":"tag-hospital-care","23":"tag-ie","24":"tag-industrial-news","25":"tag-ireland","26":"tag-life-sciences","27":"tag-linkendrnrealtime-linkedarticle-dnco20251022001799","28":"tag-medical-conditions","29":"tag-new-product","30":"tag-new-product-service-testing","31":"tag-new-products","32":"tag-new-products-services","33":"tag-newsplus","34":"tag-pharmaceuticals","35":"tag-political","36":"tag-political-general-news","37":"tag-products","38":"tag-products-services","39":"tag-research","40":"tag-research-development","41":"tag-service-testing","42":"tag-services","43":"tag-synd","44":"tag-wsj-pro-wsj-com"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/139572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=139572"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/139572\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/139573"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=139572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=139572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=139572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}